Truist Securities reiterated a "Buy" rating on Eli Lilly stock with a price target of $1,038 following its presentation on the diabetes drug, orforglipron.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
Truist Reiterates Eli Lilly (LLY) Buy Rating on Orforglipron Diabetes Drug Data
